Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-19-049117
Filing Date
2019-09-11
Accepted
2019-09-11 12:35:25
Documents
1
Period of Report
2019-09-11

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 3909
  Complete submission text file 0001209191-19-049117.txt   5251
Mailing Address C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT NOVATO CA 94949
Business Address
KAKKIS EMIL D (Reporting) CIK: 0001248093 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36276 | Film No.: 191087721

Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Issuer) CIK: 0001515673 (see all company filings)

EIN.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations